Skip Navigation


JAC Advance Access originally published online on February 17, 2009
Journal of Antimicrobial Chemotherapy 2009 63(4):826-828; doi:10.1093/jac/dkp025
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
63/4/826    most recent
dkp025v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Daskalaki, M.
Right arrow Articles by Chaves, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daskalaki, M.
Right arrow Articles by Chaves, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

Molecular characterization of resistance to mupirocin in methicillin-resistant Staphylococcus aureus isolates in a tertiary hospital in Spain

Maria Daskalaki, Joaquin R. Otero and Fernando Chaves*

Servicio de Microbiología, Hospital Universitario 12 de Octubre, Avenida de Córdoba sn, 28041 Madrid, Spain

* Corresponding author. Tel: +34-91-3908239; Fax: +34-91-5652765; E-mail: fchaves.hdoc@salud.madrid.org

Keywords: molecular epidemiology , mupirocin resistance , gentamicin resistance , MRSA

The first 10% of the full text of this article appears below.

Sir,

Mupirocin (pseudomonic acid A) is an analogue of isoleucine that inhibits protein synthesis by competitively binding to the enzyme isoleucyl-tRNA synthetase.1 Since mupirocin became available in the 1980s, its widespread use has been linked to increasing rates of resistance.2–4 Two types of resistance to mupirocin have been described: low-level resistance (LMupR; MIC, 8–256 mg/L) is usually associated with a mutation in the gene for the target enzyme, whereas high-level resistance (HMupR; MIC, >256 mg/L) is mediated by the acquisition of a plasmid . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Med MicrobiolHome page
N. E. M. d. Oliveira, E. D. C. Cavalcanti, M. S. Laport, M. d. C. d. F. Bastos, and M. Giambiagi-deMarval
Constitutive expression of the ileS-2 gene responsible for high-level mupirocin resistance in Staphylococcus aureus
J. Med. Microbiol., December 1, 2009; 58(12): 1582 - 1584.
[Abstract] [Full Text] [PDF]